Veeva Systems has entered into a multiyear enterprise agreement with BioMarin Pharmaceutical that extends and deepens their collaboration on clinical and commercial data management platforms. Under the terms of the agreement, BioMarin will deploy Veeva’s unified clinical, quality and regulatory cloud solutions across its global research and manufacturing operations, scaling usage to cover more than 20 active drug development programs. The partnership builds on an initial deployment in 2023 and is expected to streamline trial start-up timelines by 15%, reduce regulatory submission cycles by an average of two months per filing and deliver a projected 10% improvement in overall data quality metrics within the first 18 months of full implementation.

Truist Securities has upgraded Veeva Systems from Hold to Buy, highlighting the company’s attainment of its “Rule of 60” criteria—60% revenue growth plus operating margin of 20% or higher—and noting that valuation levels now offer an attractive entry point. The broker cited the waning impact of CRM platform transitions, with related revenue headwinds deferred beyond fiscal 2027 and spread evenly over subsequent years. While CRM now represents less than 30% of total revenue, Veeva retains a dominant market share among the top 20 pharmaceutical companies. Truist emphasized strong performance in Crossix—where revenue grew by more than 40% last fiscal year—and early momentum in artificial intelligence applications as drivers of durable growth and margin stability.

Veeva Systems has unveiled Veeva Environmental Monitoring, a cloud-native application integrated with Veeva LIMS to automate environmental sample collection, analysis and reporting in manufacturing laboratories. Part of the Veeva Quality Cloud suite, the solution will enable users to schedule and track thousands of daily sample events, automatically initiate quality actions in Veeva QMS and publish data to Veeva Batch Release. Mike Jovanis, president of Veeva Quality Cloud, projects that the application will reduce paper-based processes by more than 80% and accelerate batch release timelines by up to 25%. The new solution is slated for general availability in December 2026 and underscores Veeva’s commitment to modernizing quality control for over 1,500 life sciences customers worldwide.